JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

This is a multi-part, open-label, multi-center Phase 1/2a study evaluating JAB-23E73 as monotherapy (Part A) and in combination with other agents (Part B1: with cetuximab) in adult participants with advanced solid tumors. Part A will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anticancer activity of JAB-23E73 as a single agent in adult patients with advanced solid tumors with KRAS alteration. Part A consists of three phases: Phase 1a dose-escalation, Phase 1b dose expansion (dose optimization), and Phase 2a indication expansion. Part B1 will evaluate the safety, tolerability, PK, PDc, and preliminary anti-tumor efficacy of JAB-23E73 combined with cetuximab in adult participants with locally advanced or metastatic KRAS-altered CRC. Part B1 consists of two phases: Phase 1b dose escalation phase and Phase 2a dose expansion phase.